title: [Application of SPECT/PET to 70 patients with lymphoma: monitoring response to therapy].
abstract: OBJECTIVE
  To evaluate the image of SPECT/PET (18)F-FDG in monitoring response to therapy for lymphoma patients.
  
  
  METHODS
  A retrospective study was performed in 83 SPECT/PET studies for 70 patients with lymphoma from 1998 to 2008 in our hospital. The risk factors for survival rate were analyzed by univariate analysis.
  
  
  RESULTS
  Forty patients received SPECT/PET after 2 - 4 cycles of chemotheraphy, the median PFS in patients with positive and negative group were 5.5 months and 15.5 months, 2-year PFS were 12.5% and 66.8%; the median OS were 12.5 months and 17 months, and 1-year OS were 28.8% and 94.1%, respectively, all being of significant difference between two groups (P = 0.003). Forty-three patients performed posttreatment SPECT/PET, the median PFS in patients with positive and negative group were 10 months and 23 months, the 2-year PFS were 23.3% and 83.2%; the median OS were 17 months and 27 months and the 2-year OS were 60.0% and 100% respectively, all being of significant difference (P = 0.001).
  
  
  CONCLUSIONS
  SPECT/PET has significant value in monitoring response to therapy and predicting prognosis for patients with lymphoma.
authors.affiliation: Department of Hematology, The First Hospital, Peking University, Beijing 100034, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Yao
authors.forename: Xi-Nan
authors.initials: XN
authors.lastname: Cen
authors.forename: Ze-Yin
authors.initials: ZY
authors.lastname: Liang
authors.forename: Jin-Ping
authors.initials: JP
authors.lastname: Ou
authors.forename: Zhi-Xiang
authors.initials: ZX
authors.lastname: Qiu
authors.forename: Wen-Sheng
authors.initials: WS
authors.lastname: Wang
authors.forename: Wei-Lin
authors.initials: WL
authors.lastname: Xu
authors.forename: Yuan
authors.initials: Y
authors.lastname: Li
authors.forename: Yue
authors.initials: Y
authors.lastname: Yin
authors.forename: Mang-Ju
authors.initials: MJ
authors.lastname: Wang
authors.forename: Yu-Jun
authors.initials: YJ
authors.lastname: Dong
authors.forename: Li-Hong
authors.initials: LH
authors.lastname: Wang
authors.forename: Han-Yun
authors.initials: HY
authors.lastname: Ren
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008223:Lymphoma; D011379:Prognosis; D012189:Retrospective Studies; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome
chemical_list: D019788:Fluorodeoxyglucose F18